TYM-3-98, a Novel Selective Inhibitor of PI3Kδ, Demonstrates Promising Preclinical Antitumor Activity in B-Cell Lymphomas

In vivo, TYM-3-98 showed good pharmaceutical properties and remarkably reduced tumor growth in a human lymphoma xenograft model and a mouse lymphoma model.